The price of Invega Sustenna 156 mg can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. It is a long-acting injectable antipsychotic medication used to treat schizophrenia and schizoaffective disorder.
How much does Invega Sustenna 156 mg cost without insurance?
Without insurance, the list price for a single 156 mg injection of Invega Sustenna can range from approximately $700 to over $1,000. This is a considerable cost, highlighting the importance of insurance or patient assistance programs.
What assistance programs are available for Invega Sustenna?
Several assistance programs may be available to help reduce the out-of-pocket cost of Invega Sustenna. These often include co-pay assistance programs offered by the manufacturer, Janssen Pharmaceuticals, for eligible commercially insured patients. Patient assistance foundations may also provide support for uninsured or underinsured individuals. Information on these programs can typically be found on the official Invega Sustenna website or through healthcare providers.
How does insurance affect the price of Invega Sustenna?
Insurance coverage plays a crucial role in determining the final price paid by a patient for Invega Sustenna. Prescription drug plans may cover a portion of the cost, leaving the patient with a co-payment or co-insurance. The specific formulary of the insurance plan, preferred drug tiers, and any prior authorization requirements can all impact the patient's responsibility. It is advisable to verify coverage details with both the insurance provider and the pharmacy.
When does Invega Sustenna's patent expire?
The patent protection for Invega Sustenna is a critical factor influencing its long-term pricing and the potential for generic competition. DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceuticals. According to available data, patents related to Invega Sustenna and its active ingredient, paliperidone palmitate, have faced various challenges and expirations, opening avenues for generic versions. Specifically, key patents for paliperidone palmitate have expired, allowing for the development and potential market entry of generic paliperidone palmitate injections [1].
What is the difference between Invega Sustenna and Invega Trinza?
Invega Sustenna and Invega Trinza are both long-acting injectable antipsychotics containing paliperidone palmitate, but they differ in their dosing frequency. Invega Sustenna is administered every two weeks, while Invega Trinza is a once-every-three-months injection. This difference in administration schedule can affect patient convenience and potentially the overall cost over time, although individual injection prices may vary.
Can generic versions of Invega Sustenna be cheaper?
The introduction of generic versions of Invega Sustenna, often marketed as generic paliperidone palmitate, typically leads to lower prices. Once patent exclusivity ends and generic manufacturers gain approval, competition usually drives down the cost of the medication for patients and healthcare systems.
What are the clinical uses of Invega Sustenna?
Invega Sustenna is prescribed for the treatment of schizophrenia in adults and for schizoaffective disorder in adults. Its long-acting injectable formulation provides sustained release of the medication, aiming to improve treatment adherence and reduce the risk of relapse.
***
Source:
[1] DrugPatentWatch.com